Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/cadherin and β-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
所公开的是β-catenin/T-细胞因子相互作用的
抑制剂。这些
抑制剂对β-catenin/T-细胞因子的选择性高于β-catenin/cadherin和β-catenin/APC相互作用。还公开了使用所公开的化合物治疗癌症的方法。